Journal of Commercial Biotechnology (2008) 14, 79–93. doi:10.1057/palgrave.jcb.3050075
Legal and regulatory update
Content is compiled and written by Reed Smith
Reed Smith is one of the leading life sciences law fi rms and one of the 15 largest fi rms worldwide with over 1500 lawyers across 14 US and seven European and Middle Eastern cities. A strong presence on both coasts of the United States and offi ces in the UK, France and Germany makes us ideally positioned to offer clients a full-service, transatlantic capability.
We represent clients, large and small, across a great number of legal disciplines and many industry sectors. In Europe, our key industries are fi nancial services and life sciences. Our fi rmwide clients include fi nancial institutions, biotechnology and pharmaceutical companies, manufacturers, health care providers and insurers, communications companies, universities and real estate developers and government bodies on both sides of the Atlantic.
This section is intended to be a synopsis of recent legal developments and is not intended to be exhaustive. If any issue referred to in this section to be relied upon, specifi c advice should be sought.
Please contact:
John Wilkinson
Reed Smith
Minerva House
5 Montague Place
London SE1 9BB
Tel: +44 (0)20 7403 2900
Fax: +44 (0)20 7403 4221
Email: jwilkinson@reedsmith.com
